Global Male Hypogonadism Market to Reach $3.5 Billion by 2027
Amid the COVID-19 crisis, the global market for Male Hypogonadism estimated at US$2.8 Billion in the year 2020, is projected to reach a revised size of US$3.5 Billion by 2027, growing at a CAGR of 2.9% over the period 2020-2027. Testosterone Replacement Therapy, one of the segments analyzed in the report, is projected to record 2.7% CAGR and reach US$2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Gonadotropin & Gonadotropin Releasing Hormones Therapy segment is readjusted to a revised 3.2% CAGR for the next 7-year period.
The U.S. Market is Estimated at $830.8 Million, While China is Forecast to Grow at 2.8% CAGR
The Male Hypogonadism market in the U.S. is estimated at US$830.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$618.1 Million by the year 2027 trailing a CAGR of 2.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 2.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3% CAGR.
Select Competitors (Total 47 Featured):
Amid the COVID-19 crisis, the global market for Male Hypogonadism estimated at US$2.8 Billion in the year 2020, is projected to reach a revised size of US$3.5 Billion by 2027, growing at a CAGR of 2.9% over the period 2020-2027. Testosterone Replacement Therapy, one of the segments analyzed in the report, is projected to record 2.7% CAGR and reach US$2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Gonadotropin & Gonadotropin Releasing Hormones Therapy segment is readjusted to a revised 3.2% CAGR for the next 7-year period.
The U.S. Market is Estimated at $830.8 Million, While China is Forecast to Grow at 2.8% CAGR
The Male Hypogonadism market in the U.S. is estimated at US$830.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$618.1 Million by the year 2027 trailing a CAGR of 2.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 2.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3% CAGR.
Select Competitors (Total 47 Featured):
- AbbVie, Inc.
- Allergan PLC
- AstraZeneca PLC
- Bayer AG
- Eli Lilly and Company
- Endo International PLC
- Ferring International Center SA
- IBSA Institut Biochimique SA
- Laboratoires Genevrier
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Current & Future Analysis for Male Hypogonadism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 2: World Historic Review for Male Hypogonadism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 3: World 15-Year Perspective for Male Hypogonadism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
- Table 4: World Current & Future Analysis for Testosterone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 5: World Historic Review for Testosterone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 6: World 15-Year Perspective for Testosterone Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
- Table 7: World Current & Future Analysis for Gonadotropin & Gonadotropin Releasing Hormones Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 8: World Historic Review for Gonadotropin & Gonadotropin Releasing Hormones Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 9: World 15-Year Perspective for Gonadotropin & Gonadotropin Releasing Hormones Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
- Table 10: World Current & Future Analysis for Topical Gels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 11: World Historic Review for Topical Gels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 12: World 15-Year Perspective for Topical Gels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
- Table 13: World Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 14: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 15: World 15-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
- Table 16: World Current & Future Analysis for Transdermal Patches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 17: World Historic Review for Transdermal Patches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 18: World 15-Year Perspective for Transdermal Patches by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
- Table 19: World Current & Future Analysis for Other Drug Deliveries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 20: World Historic Review for Other Drug Deliveries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 21: World 15-Year Perspective for Other Drug Deliveries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
- UNITED STATES
- Table 22: USA Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 23: USA Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 24: USA 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
- Table 25: USA Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 26: USA Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 27: USA 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
- CANADA
- Table 28: Canada Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 29: Canada Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 30: Canada 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
- Table 31: Canada Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 32: Canada Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 33: Canada 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
- JAPAN
- Table 34: Japan Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 35: Japan Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 36: Japan 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
- Table 37: Japan Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 38: Japan Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 39: Japan 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
- CHINA
- Table 40: China Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 41: China Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 42: China 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
- Table 43: China Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 44: China Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 45: China 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
- EUROPE
- Table 46: Europe Current & Future Analysis for Male Hypogonadism by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- Table 47: Europe Historic Review for Male Hypogonadism by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 48: Europe 15-Year Perspective for Male Hypogonadism by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
- Table 49: Europe Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 50: Europe Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 51: Europe 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
- Table 52: Europe Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 53: Europe Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 54: Europe 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
- FRANCE
- Table 55: France Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 56: France Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 57: France 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
- Table 58: France Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 59: France Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 60: France 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
- GERMANY
- Table 61: Germany Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 62: Germany Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 63: Germany 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
- Table 64: Germany Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 65: Germany Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 66: Germany 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
- ITALY
- Table 67: Italy Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 68: Italy Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 69: Italy 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
- Table 70: Italy Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 71: Italy Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 72: Italy 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
- UNITED KINGDOM
- Table 73: UK Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 74: UK Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 75: UK 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
- Table 76: UK Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 77: UK Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 78: UK 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
- REST OF EUROPE
- Table 79: Rest of Europe Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 80: Rest of Europe Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 81: Rest of Europe 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
- Table 82: Rest of Europe Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 83: Rest of Europe Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 84: Rest of Europe 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
- ASIA-PACIFIC
- Table 85: Asia-Pacific Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 86: Asia-Pacific Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 87: Asia-Pacific 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
- Table 88: Asia-Pacific Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 89: Asia-Pacific Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 90: Asia-Pacific 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
- REST OF WORLD
- Table 91: Rest of World Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 92: Rest of World Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 93: Rest of World 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
- Table 94: Rest of World Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- Table 95: Rest of World Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- Table 96: Rest of World 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
- Total Companies Profiled: 47
Note: Product cover images may vary from those shown